Clarus Therapeutics Holdings, Inc.
CRXTDelisted Sep 14, 2022- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001817944
Clarus Therapeutics Holdings, Inc. was delisted on Sep 14, 2022; its insiders filed their last Form 4 on Jun 9, 2022; 25 institutions reported holding it in 13F filings for Q2 2022, worth $1.82M in total; no superinvestor held it.
13F holders, Q1 2022
Institutional positions in Clarus Therapeutics Holdings, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 13
- +1 vs. Q4 2021
- Shares held
- 2.50M
- −1.80M (−41.8%) vs. Q4 2021
- Total value
- $3.73M
- −$6.73M (−64.3%) vs. Q4 2021
- New holders
- 7
- 3 more added
- Sold out
- 6
- 1 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CRXT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 1 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 2 | $5.00K |
| Q2 2022 | 25 | $1.82M |
| Q1 2022 | 13 | $3.73M |
| Q4 2021 | 12 | $10.5M |
| Q3 2021 | 12 | $12.1M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Clarus Therapeutics Holdings, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bracebridge Capital, LLC | 2,002,495 | $2.98M | 1.03% | 00.0% | Unchanged |
| Vanguard Group Inc | 174,500 | $260.0K | 0.00% | +7,900+4.7% | Added |
| Bridgeway Capital Management, LLC | 90,000 | $134.0K | 0.00% | +90,000 | New |
| UBS Group AG | 66,537 | $99.0K | 0.00% | +20,906+45.8% | Added |
| Millennium Management LLC | 39,228 | $58.0K | 0.00% | +39,228 | New |
| Renaissance Technologies LLC | 34,700 | $52.0K | 0.00% | +34,700 | New |
| Geode Capital Management, LLC | 33,915 | $50.0K | 0.00% | +33,915 | New |
| Verition Fund Management LLC | 30,000 | $45.0K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 20,353 | $30.0K | 0.00% | +20,353 | New |
| Citigroup Inc | 7,400 | $11.0K | 0.00% | +7,400 | New |
| Tower Research Capital LLC (TRC) | 3,936 | $6.00K | 0.00% | −8,987−69.5% | Reduced |
| Royal Bank of Canada | 500 | $1.00K | 0.00% | +500 | New |
| Wells Fargo & Company | 40 | $0 | 0.00% | +15+60.0% | Added |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −1,929,876−100.0% | Sold out |
| Powell Investment Advisors, LLC | 0 | $0 | 0.00% | −64,000−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −20,800−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −18,148−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −12,597−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −2−100.0% | Sold out |